Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIONs/SMF with Neoadjuvant Chemotherapy in Osteosarcoma
NCT04316091Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Nanoparticles
01
Overview
Phase 1, randomised, open-label trial of superparamagnetic iron oxide in osteosarcoma (OS) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Recommended Phase 2 Dose at 36 months. Status: unknown.
02
Drugs
superparamagnetic iron oxide
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT04316091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316091.